Resistance to arsenite, arsenate, and antimonite in bacteria results from the action of a plasmid-encoded ATP-driven oxyanion extrusion pump, resulting in lowering of the intracellular concentration of the toxic compounds (4, 17) . The genes for this novel anion pump were originally cloned from the IncF1 plasmid R773 of Escherichia coli (15) . This oxyanion pump is unrelated to the other known families of ion pumps, such as the FoF1 and the ElE2 types of iontranslocating ATPases (9) . Only two gene products, the 63-kDa catalytic ArsA protein and the 45.5-kDa inner membrane ArsB protein, are required for arsenite and antimonite resistance (16) . Purified ArsA protein has been shown to exhibit oxyanion-stimulated ATPase activity (19) and to bind ATP by UV-catalyzed adduct formation (19) as well as by the use of the fluorescent analog 2',3'-O-(2,4,6-trinitrophenylcyclohexadienylidene)adenosine-5'-triphosphate (8) . The active form of the ArsA ATPase is a homodimer of two ArsA polypeptides (5) .
The nucleotide sequence of the arsA gene shows two regions that are similar to one another. Both halves of the arsA gene product contain a similar but not identical consensus nucleotide binding sequence (2) that corresponds to a portion of a nucleotide binding domain (22) . Hence, the arsA gene has been proposed to have arisen by a gene duplication and fusion event (2) . By independent mutagenesis of the two nucleotide binding folds, it was previously shown that both domains are required for function (7, 10) . Mutations in the N-terminal or Al domain resulted in complete loss of ATPase activity and loss of photoadduct formation with [c-32P]ATP (7) . Mutations in the C-terminal or A2 domain also resulted in loss of ATPase activity, but the mutant ArsA proteins retained the ability to form a photoadduct with ATP (10) . These studies indicate that the site of UV-catalyzed reaction with ATP is in the Al nucleotide binding fold. In this study we created N-and C-terminal deletion MATERIALS AND METHODS Strains, plasmids, and phage. The E. coli strains, plasmids, and phage used in this study are shown in Table 1 .
Media and growth conditions. Cells were grown in LB medium (14) at 37°C. Antibiotics were added to 50 4g/ml unless otherwise noted. Sodium arsenite was added at the indicated concentrations to test for arsenical resistance.
DNA manipulations. The conditions used for plasmid isolation, DNA restriction endonuclease analysis, ligation, transformation, and sequencing were as described previously (20 1.1 kb of the arsA gene, encoding the first 323 residues of the N-terminal or Al portion of the ArsA protein, was subcloned from M13 phage derivative mCMC49-3dl-22 as an EcoRIHindIII fragment behind the lac promoter of pUC18, generating plasmid pArsAl. The portion of the gene for the Al half of the ArsA protein is termed the arsAl gene.
To generate a plasmid encoding the C-terminal or A2 portion of the ArsA protein, plasmid pUM3 (15) was digested with AvaI. The ends were filled in with the Klenow fragment of DNA polymerase, and the DNA was further digested with HindIII. The 3.66-kb fragment was purified from a low-melting-point agarose gel and ligated into plasmid pUC18 that had been digested with Sal, filled in with the Klenow fragment of DNA polymerase, and digested with HindIII. The resulting plasmid, encoding the last 417 residues of the ArsA protein, was designated pArsA2. The portion of the ar&A gene encoding the A2 half of the ArsA protein (termed the arsA2 gene) in plasmid pArsA2 was expressed under control of the lac promoter and utilized the translational start signals from the lacZ gene. This translational fusion carries 17 residues from P-galactosidase at its N terminus. The plasmid pArsA2 also contains the wild-type arsB and arsC genes.
For complementation studies, both the arsAl and arsA2 genes were cloned as EcoRI-HindIII fragments under control of the lac promoter in the colEl-compatible pACYC184 derivative pSU2718 (12) and were designated pSU2718Al and pSU2718A2, respectively. The ArsA protein was purified as described previously (6, 10) .
Photoadduct formation of the Al or A2 half of the ArsA protein and [a-32PJATP. Photolabeling was performed with either purified wild-type ArsA protein (6, 10) or cytosol from the cells expressing the arsAl or arsA2 gene. Cells of E. coli carrying the indicated plasmids were grown in LB medium (14) to an optical density at 600 nm of 0.6 to 0.8 and induced with 0. 25 
mM isopropyl (-D-thiogalactopyranoside (IPTG).
After 2 h at 37°C, the cells were harvested and lysed by a single passage through a French pressure cell at 20,000 lb/in2. The lysate was centrifuged at 10,000 x g for 20 min to remove unbroken cells, and the supernatant solution was used directly for formation of photoadducts. Cytosol (25 to 50 jig of protein) was mixed with 5 ,uM ATP, 5 mM MgCl2, and 10 ,Ci of [a-32P]ATP in a total volume of 0.1 ml in a 96-well microtitration plate. The samples were exposed to UV light at 254 nm from a lamp placed directly on top of the microtitration plate for 30 min at 4°C (19) . The protein was precipitated by adding 0.4 ml of 10% trichloroacetic acid. The precipitated protein was recovered by centrifugation and washed three times with 10% trichloroacetic acid. The pelleted material was suspended in sodium dodecyl sulfate (SDS) sample buffer and analyzed by polyacrylamide gel electrophoresis (PAGE) on a 12% polyacrylamide gel (11).
Genetic conmplementation. Cultures of E. coli JM109 bearing plasmids carrying the arsAl or arsA2 gene or one of a variety of mutations in the arsA gene, alone or in combination, were grown in LB medium for 12 h at 37°C. Each culture was diluted 100-fold into 2 ml of LB medium containing 0, 3, 5, 7, or 9 mM sodium arsenite and 0.1 mM IPTG and incubated at 37°C with aeration. The turbidity of the cultures at 600 nm was measured after 12 h. A portion of each culture (0.5 ml) was centrifuged, and the pellets were suspended in 0.1 ml of SDS sample buffer and boiled for 10 min. Portions (10 ,ul) were analyzed by SDS-PAGE on 12% polyacrylamide gels and immunoblotted with anti-ArsA antiserum.
Complementation was also examined on solid LB agar medium containing 0. 
FIG. 1. Diagrammatic representation of the ArsA, ArsAl, and ArsA2 proteins. The ArsA protein has 583 residues and two consensus sequences for nucleotide binding sites (boxed sequences). Within those two sequences are shown mutations GD18, GS20, GR337, and KE340 (arrows). The nucleotide sequence for the first 323 residues was cloned to produce plasmid pArsAl, which encodes the 342-residue ArsAl protein containing 323 residues of the ArsA protein. Because the message does not terminate for an additional nine codons, the ArsAl polypeptide contains nine additional residues. The nucleotide sequence for ArsA residues 167 through 583 was ligated to the sequence for the first 17 residues of the lacZ gene, generating plasmid pArsA2, which encodes the 434-residue ArsA2 protein.
isolated single colonies. The plates were incubated at 37°C for 18 to 24 h and visually scored for growth.
Materials. All restriction enzymes and nucleic acid-modifying enzymes were obtained from Bethesda Research Laboratories. All other chemicals were obtained from commercial sources.
RESULTS
Creation of deletion derivatives of ArsA protein. To elucidate the roles of the two nucleotide binding domains of the ArsA protein and to study the interactions between them, deletion clones of the arsA gene were created. In addition a number of previously isolated mutants with point mutations in either the Al or A2 nucleotide binding folds (7, 10) were utilized ( Table 1) .
The subclones of the arsA gene encoded either the N-terminal (Al) or the C-terminal (A2) nucleotide binding fold, with an overlap between the two (Fig. 1 Neither the arsAl nor the arsA2 portion of the arsA gene alone conferred high-level arsenite resistance on cells, whereas cells expressing a wild-type arsA gene with the arsB gene were resistant to at least 10 mM sodium arsenite ( Fig.  2A and B) . In this assay medium, resistant cells were still capable of growth at 15 mM sodium arsenite (data not shown). These results indicate that neither half of the ArsA protein alone is sufficient for function. Both the Al and A2 peptides were produced, as determined by immunoblotting with anti-ArsA antiserum (Fig. 3) . When subjected to SDS-PAGE, each exhibited approximately the size predicted from the nucleotide sequence; 36. formed a photoadduct in a Mg2e-dependent manner to the same extent as the wild-type protein did (Fig. 4) . In contrast, no photoadduct formation was observed with cytosol containing the A2 polypeptide (Fig. 5) beled in the absence of Mg2" (Fig. 4, lane 5; Fig. 5, lane 8) but not in its presence (Fig. 4, lane 6; Fig. 5, lane 7) . This band is also present in cytosol from cells without any ars genes'and is unrelated to the ArsA2 polypeptide (data not shown).
These data are in agreement with the results with intact ArsA proteins that had mutations in either the Al or A2 nucleotide binding consensus sequences, where mutations in the Al sequence eliminated photoadduct formation but mutations in the A2 did not (7, 10) . When cytosols containing the Al and A2 polypeptides were mixed before labeling with [a-32P]ATP, only the Al polypeptide formed a photoadduct (data not shown); these results are identical to those with the Al polypeptide alone (Fig. 4, lanes 5 and 6) .
Gienetic complementation. Arsenical resistance requires two intact nucleotide binding consensus sequences in the ArsA protein (7, 10 Fig. 2A) . At higher arsenite concentrations, cells with either mutant plasmid were fully inhibited and indistinguishable from those with vector alone. When the two plasmids were expressed in the same cell, the cells were as resistant to arsenite as were cells with plasmid pPK56, which has a wild-type ars operon (Fig. 2A) . Complementation between a plasmid with the mutation TI22 (7) in the Al sequence and the mutation KE340 in the A2 sequence was also observed (data not shown).
Similarly, plasmid pArsAl (expressing the 36.5-kDa Al polypeptide) complemented plasmids pCMC1065 and pCMC1079 (with GS20 and GD18 mutations, respectively) in the Al site (Fig. 2B) . For unexplained reasons, plasmid pCMC1079 (GD18) did not complement plasmid pKE340 (KE340) (data not shown). Plasmid pSU2718A2, expressing the 47.6-kDa A2 polypeptide, complemented plasmid pKE340, which has the KE340 point mutation in the A2 nucleotide binding domain (Fig. 2B) . Coexpression of both the arsAl gene in plasmid pArsAl and the arsA2 gene in plasmid pSU2718A2 also restored high-level arsenite resistance (Fig. 2B) .
As expected, subclones did not complement point mutations in the other nucleotide binding domain. Cells coexpressing plasmid pSU2718A1, which expresses the arsAl gene, and plasmid pKE340, which has a wild-type Al domain and a mutation in the A2 domain, were no more resistant to arsenite than were cells with pKE340 alone (Fig.  2C) . Similarly, cells coexpressing plasmid pArsA2, which encodes an A2 domain, and plasmid pCMC1056, which encodes a wild-type A2 domain and a mutated Al domain, were as sensitive to arsenite as were cells with pArsA2 alone (Fig. 2C) . Note that constructs with the arsA2 gene appear to confer some resistance (Fig. 2B and C) . This is actually the result of expression of the arsB gene. In the absence of a bound ArsA protein, the ArsB protein alone confers partial resistance to and transport of arsenite (3a) . We hypothesize that the ArsB protein alone functions as a secondary oxyanion porter (18) . Plasmid pGR337, expressing the ArsA2 point mutation GR337, was not complemented by any other plasmid. This lack of complementation may result from improper interactions between the mutant GR337 protein and other ArsA proteins.
Immunoblot analysis of coexpression of the proteins. To demonstrate that the compatible plasmids were expressing the expected Arsl, ArsA2, and/or mutant ArsA polypeptides, immunoblot analysis was performed with anti-ArsA serum. Discrete bands corresponding to the full-length mutant ArsA proteins and to the two truncated ArsAl and ArsA2 peptides were observed (Fig. 3) .
DISCUSSION
The nucleotide sequence of the arsA gene shows that the N-terminal and C-terminal halves of the ArsA protein are similar to one another, indicating that the arsA gene arose through a gene duplication and fusion event (2) . Both halves of the ArsA protein contain similar but not identical consensus nucleotide binding sequences (23) . This consensus sequence, GXXGXGKT(S), found in many nucleotide binding proteins, forms part of a nucleotide binding domain, as shown by the X-ray crystal structure determination of adenylate kinase (22) . Mutagenesis of each nucleotide binding sequence in the ArsA protein separately has shown that both the Al and A2 nucleotide binding consensus sequences contribute independently to the catalytic activity of this protein (7, 10) (7) . The ArsA protein has been shown to bind 2 mol of nucleotide per mol of protein (8) . Hence, either the A2 nucleotide binding domain is a lower-affinity ATP binding site or the amino acid residues in the vicinity of that site are not capable of adduct formation in the UV-catalyzed reaction.
Domain analysis has been used to demonstrate interactions of multiple sites within single polypeptides. Results similar to those described in this report have been obtained with the SecA protein, the catalytic subunit of the protein translocation ATPase of E. coli (13) . When polypeptides containing two fragments of the SecA protein with overlapping N-and C-terminal halves were mixed in vitro, the N-terminal polypeptide, which contains a nucleotide binding consensus sequence, formed a photoadduct with [L-32PJ ATP. Since the SecA protein has been proposed to function as a dimer, dimerization may stabilize the association of the interacting polypeptides.
Similarly, in vivo formation of heterodimeric mercuric reductase proteins between point mutants has been reported (3) . In that study a two-plasmid system in which two mutant genes were placed on separate compatible plasmids was utilized. Coexpression led to mercury-resistant phenotypes that were distinguishable from the phenotype of either mutant alone. Reconstitution of an active lactose carrier in vivo by simultaneous expression of two lacYDNA segments has also been shown (1, 24) .
Previous studies have demonstrated that the ArsA protein functions as a dimer in solution and presumably also in the membrane-bound complex (5). This conclusion is supported by the complementation experiments. Since the Al and A2 halves of the ArsA protein appear to contain independent nucleotide binding domains, it was of interest to determine whether coexpression of point mutations in the Al or A2 consensus sequences would lead to restoration of function and hence arsenite resistance. Various combinations of plasmids were coexpressed such that, out of four potential nucleotide binding domains in a dimer (two Al sites and two A2 sites), the cells contained at least one wild-type Al sequence and one-wild type A2 sequence. This was achieved by using plasmids encoding (i) two full-length mutated arsA genes, (ii) one full-length arsA gene and one half-length arsAl or arsA2 gene, or (iii) two half-length arsA genes.
These combinations are represented diagramatically in Fig.  6 . Importantly, point mutants in two halves of the ArsA protein complement each other, and their coexpression (Fig. 6D through G) . The results indicate that dimerization of ArsA protein facilitates complementation between the Al and A2 domains. This is reminiscent of the interaction of the a and 1B subunits of the F1 ATPase, where ATPase activity requires positive interactions of the two (21) . ATP binding to the a subunit produces a conformational change that is transmitted to the ,B subunit as a positively cooperative effect on ATP hydrolysis or synthesis.
The isolation and purification of the ArsAl and ArsA2 polypeptides are in progress. Biochemical reconstitution of a functional oxyanion-stimulated ATPase by mixing of the two polypeptides would demonstrate their independent contributions to a common function.
